66322Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Co-construction Collaborative Innovation Center for Respiratory Disease Diagnosis and Treatment & Chinese Medicine Development of Henan Province/Henan Key Laboratory of Chinese Medicine for Respiratory Disease, 232830Henan University of Chinese Medicine, Zhengzhou, China.
Clin Rehabil. 2022 Aug;36(8):999-1015. doi: 10.1177/02692155221095481. Epub 2022 Apr 28.
To evaluate the efficacy and safety of pulmonary rehabilitation for exercise tolerance and quality of life improvement in idiopathic pulmonary fibrosis.
We searched PubMed, Cochrane Library, Embase, Web of Science, Chinese Biomedical Literature Database, China National Knowledge Infrastructure, Wanfang Database, and Chongqing VIP for randomized controlled trials that compared pulmonary rehabilitation with usual care for idiopathic pulmonary fibrosis. The risk of bias and certainty of evidence were assessed using Cochrane Collaboration's Risk of Bias tool and the Grading of Recommendations, Assessment, Development and Evaluation criteria.
Eleven trials in total with 549 participants. Compared with usual care, pulmonary rehabilitation significantly increased 6-minute walking distance (mean difference: 35.2m, 95% confidence intervals: 25.4m-44.9m; ten trials; 447 participants; moderate), decreased the St George's Respiratory Questionnaire total scores (mean difference: -9.11, 95% confidence intervals: -10.78 to -7.43; six trials; 303 participants; moderate), and reduced the modified Medical Research Council scores were lower (mean difference: -0.76, 95% confidence intervals: -1.25 to -0.27; three trials; 196 participants; low). Improvements were noted in forced vital capacity percent-predicted (mean difference: 4.88, 95% confidence intervals: 2.67 to 7.10; four trials; 214 participants; moderate) and diffusing capacity for carbon monoxide (mean difference: 4.71, 95% confidence intervals: 0.96 to 8.46; six trials; 358 participants; low).
Pulmonary rehabilitation may significantly improve exercise tolerance and quality of life in idiopathic pulmonary fibrosis patients, but the quality of evidence was low to moderate. Large sample, multicenter, randomized controlled trials are needed to verify the efficacy and safety of pulmonary rehabilitation.
评估肺康复对特发性肺纤维化患者运动耐量和生活质量改善的疗效和安全性。
我们检索了 PubMed、Cochrane 图书馆、Embase、Web of Science、中国生物医学文献数据库、中国国家知识基础设施、万方数据库和重庆 VIP,以比较肺康复与特发性肺纤维化常规护理的随机对照试验。使用 Cochrane 协作风险偏倚工具和推荐评估、制定与评价分级标准评估风险偏倚和证据确定性。
共纳入 11 项试验,共计 549 名参与者。与常规护理相比,肺康复显著增加了 6 分钟步行距离(平均差异:35.2m,95%置信区间:25.4m-44.9m;10 项试验;447 名参与者;中度),降低了圣乔治呼吸问卷总评分(平均差异:-9.11,95%置信区间:-10.78 至 -7.43;6 项试验;303 名参与者;中度),并且改良医学研究委员会评分较低(平均差异:-0.76,95%置信区间:-1.25 至 -0.27;3 项试验;196 名参与者;低)。用力肺活量预计值百分比(平均差异:4.88,95%置信区间:2.67 至 7.10;4 项试验;214 名参与者;中度)和一氧化碳弥散量(平均差异:4.71,95%置信区间:0.96 至 8.46;6 项试验;358 名参与者;低)也有所改善。
肺康复可能显著改善特发性肺纤维化患者的运动耐量和生活质量,但证据质量为低到中度。需要更大样本、多中心、随机对照试验来验证肺康复的疗效和安全性。